Buzzard Pharmaceuticals
Sweden
unknown
unknown
Stage
1
Investors
About
Buzzard Pharmaceuticals is developing Isunakinra, a potent interleukin-1 (IL‑1) inhibitor — a chimeric protein that binds IL1R1 — repurposed from ophthalmology to oncology to treat solid tumours in combination with PD‑1 checkpoint inhibitors. Isunakinra was acquired from Eleven Biotherapeutics in 2017 and is currently being evaluated in Phase 1/2 trials at the Baylor Research Institute in Dallas, Texas.
Explore Buzzard Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.